Molecular targeted agents—where we are and where we are going
A total of 23 new cancer medicines or indication expansions were approved by the U. S. Food and Drug Administration in 2012. Among these, 12 are new molecular entities (NMEs)—new chemical or biological drugs approved for the first time for oncologic use—and 10 of these NMEs are molecular targeted ag...
Main Author: | Yan, Li |
---|---|
Format: | Online |
Language: | English |
Published: |
Sun Yat-sen University Cancer Center
2013
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845551/ |
Similar Items
-
Where are we and where are we going?
by: Dale, Littler, et al.
Published: (2005) -
Iron health: where are we and where are we going?
by: Gotardo, Glória Ines Beal
Published: (2011) -
Hip Arthroscopy: Where We Are, and Where We Are Going
by: Park, Myung Sik, et al.
Published: (2015) -
Linking: where are we now and where are we going?
by: Harry E., Samuels
Published: (2002) -
Where Have We Been, Where Are We Going…
by: Edward, Peck
Published: (2003)